Purchasers of Receivables Assets

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the life sciences industry. The company specializes in acquiring revenue-producing royalty streams from academic institutions, research hospitals, and biotechnology companies, often using specialized vehicles like Purchasers of Receivables Assets, LLC. By providing upfront capital in exchange for future top-line royalties, Royalty Pharma enables its partners to fund further research and development or commercialization efforts. Its extensive portfolio includes interests in over 35 blockbuster therapies, including treatments for migraine, cystic fibrosis, and various cancers. The company is a key player in the financial ecosystem of the biotech industry, bridging the gap between clinical development and commercial success.